The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CML/MPN 2025 | Factors affecting adherence to TKI therapy in patients with CML
In this video, Giuseppe Saglio, MD, University of Turin, Turin, Italy, briefly comments on the importance of adherence to tyrosine kinase inhibitor (TKI) treatment in patients with chronic myeloid leukemia (CML). Prof. Saglio highlights that adherence to asciminib is good due to its tolerability and convenient administration. This interview took place at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We know that approximately 30% of the patients are changing TKI therapy. In the ASC4FIRST trial, we see that this difference is particularly important between asciminib and imatinib, which is a quite well-tolerated drug, but it’s also very, very important with asciminib with the second generation TKIs that, with respect to the imatinib, are now the drugs which are generally used to achieve a very deep and soon molecular response so they are generally used in younger patients...
We know that approximately 30% of the patients are changing TKI therapy. In the ASC4FIRST trial, we see that this difference is particularly important between asciminib and imatinib, which is a quite well-tolerated drug, but it’s also very, very important with asciminib with the second generation TKIs that, with respect to the imatinib, are now the drugs which are generally used to achieve a very deep and soon molecular response so they are generally used in younger patients.
So I think that I would say the problem of having a continuous TKI therapy and the most important thing for CML patients to stay in a continuous and very, I would say, adherent way on TKI therapy. And this is what we can obtain with very well-tolerated drugs, drugs also which are easy to be taken, like I would say one pill a day is better than twice a day, no real interaction with food or other problems, because if you forgot for one moment just to take the pill at a very early stage, then you can do it without the problem of food interaction and so on. So I think that all these things make a very easy to use, friendly to use drug, asciminib, and this is one of them which has been demonstrated both in third line and in first line a low rate of the TKI discontinuation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
